Cagrilintide is a new long-acting acylated amylin analog under development, mainly used as a non-selective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Its main functions and effects include:

Weight loss: Cagrilintide significantly reduces food intake and weight loss by activating amylin receptors and calcitonin G protein-coupled receptors, showing potential in obesity research.

Reducing food intake: The drug can suppress appetite and effectively delay gastric emptying, thereby reducing food intake.

Improving blood sugar control: When Cagrilintide is used in combination with the GLP-1 receptor agonist Semaglutide, it shows a more significant improvement in glycated hemoglobin levels, but the effect on HbA1c levels is not as good as using Semaglutide alone.

Treatment of obesity and type 2 diabetes: CagriSema (cagrilintide and semaglutide combination therapy) is designed for once-weekly subcutaneous injection and is primarily used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).

Prevention of weight regain: CagriSema may help prevent the "yo-yo effect" in which patients regain weight after stopping medication.

Our Main Product